Yurii Ostapenko

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 375 citations · Full text

Medicine, Oncology, Pharmacology +14

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC

James Chih‐Hsin Yang, Shun Lu, Hidetoshi Hayashi et al. · New England Journal of Medicine · 2025 · 85 citations

Medicine, Oncology, Pharmacology +15

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

Bruno Sangro, Peter R. Galle, Robin Kate Kelley et al. · Journal of Clinical Oncology · 2024 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · Future Oncology · 2023 · 17 citations · Full text

Medicine, Oncology, Pharmacotherapy +15